Table 2.
Correlations between ENE in ALN and clinicopathological parameters.
| Variables | No. of patients (%) | ENE | Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | OR | 95% CI | p-value | OR | 95% CI | p-value | |||
| Total population | 402 (100) | 244 (60.7%) | 158 (39.3%) | |||||||
| Median age (Y) | 52 (30–83) | 50 (30–80) | 54 (32–83) | |||||||
| T stage | 0.465 | |||||||||
| T1 | 119 (29.6) | 70 (17.4) | 49 (12.2) | 1 | – | – | ||||
| T2 | 261 (64.9) | 162 (40.3) | 99 (24.6) | 0.873 | 0.561–1.359 | 0.547 | ||||
| T3 | 22 (5.5) | 12 (3.0) | 10 (2.5) | 1.190 | 0.477–2.973 | 0.709 | ||||
| Histological grade | 2 | 207 (51.5) | 115(28.6) | 92 (22.9) | 1 | – | – | |||
| 3 | 195 (48.5) | 130 (32.3) | 65 (16.2) | 1.632 | 1.089–2.445 | 0.018 | 0.559 | 0.347–0.889 | 0.016 | |
| N stage | < 0.001 | < 0.001 | ||||||||
| 1 | 107 (26.6) | 87 (21.6) | 20 (5.0) | 1 | – | – | ||||
| 2 | 191 (47.5) | 119 (29.6) | 72 (17.9) | 2.574 | 1.459–4.451 | 0.001 | 2.456 | 1.360–4.434 | 0.003 | |
| 3 | 104 (25.9) | 38 (9.5) | 66 (16.4) | 7.877 | 4.194–14.796 | < 0.001 | 7.301 | 3.618–14.735 | < 0.001 | |
| ER status | Negative | 96 (23.9) | 63 (15.7) | 33 (8.2) | 1 | – | – | |||
| Positive | 306 (76.1) | 181 (45.0) | 125 (31.1) | 0.758 | 0.470–1.224 | 0.258 | ||||
| PR status | Negative | 121 (30.1) | 78 (19.5) | 43 (10.6) | 1 | – | – | |||
| Positive | 281 (69.9) | 166 (41.3) | 115 (28.6) | 0.796 | 0.512–1.238 | 0.331 | ||||
| HER2 status | Negative | 307 (76.4) | 180 (44.8) | 127 (31.6) | 1 | – | – | |||
| Positive | 95 (23.6) | 64 (15.9) | 31 (7.7) | 1.457 | 0.897–2.367 | 0.129 | ||||
| Lympho-vascular invasion | Negative | 206 (51.2) | 142 (35.3) | 64 (15.9) | 1 | – | – | |||
| Positive | 196 (48.8) | 102 (25.4) | 94 (23.4) | 2.045 | 1.361–3.072 | 0.001 | 1.258 | 0.793–1.994 | 0.330 | |
| Molecular subtype | Luminal-A like | 72 (17.9) | 37 (9.2) | 35 (8.7) | 1 | – | – | |||
| Luminal-B like | 182 (45.3) | 114 (28.4) | 68 (16.9) | 0.631 | 0.363–1.094 | 0.101 | 0.661 | 0.361–1.211 | 0.180 | |
| HER2-overexpression | 52 (12.9) | 36 (9.0) | 16 (3.9) | 0.470 | 0.222–0.993 | 0.048 | 0.418 | 0.179–0.977 | 0.044 | |
| Triple negative breast cancer | 45 (11.2) | 31 (7.7) | 14 (3.5) | 0.477 | 0.218–1.044 | 0.064 | 0.566 | 0.232–1.381 | 0.211 | |
| Others | 51 (12.7) | / | / | |||||||
ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2; ENE extranodal extension.